A Phase IIIb Study of Venetoclax and Azacitidine or Decitabine in an Outpatient Setting in Patients with Acute Myeloid Leukemia

This study evaluated the efficacy and safety of venetoclax plus hypomethylating agent in a United States community–based outpatient setting in patients with newly diagnosed AML who were treatment naïve for AML.